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Summary The prognostic weight of histological and biological factors was compared with that of known
clinical prognostic factors in a population of 108 consecutive previously untreated patients with head and neck
squamous cell carcinoma. Parameters studied were: tumour vascularisation, mitotic index, histological
differentiation, nuclear grade, keratinisation, desmoplasia, growth pattern, inflammation, tumour emboli in
peripheral vessels, keratins 6, 13, 19 immunohistochemical expression, cytofluorometric ploidy and S-phase. In
multivariate analysis (Cox), only age and nodal status had a significant impact on overall survival, whereas T
stage was the only significant factor associated with locoregional failure. The cumulative incidence of
metastases was correlated not only with age, T and N stage, but also with histological differentiation. All the
other histological and biological factors studied failed to provide further prognostic information. These findings
may help to select patients with high metastatic risk.
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Numerous factors have been evaluated for their potential
prognostic influence in patients with newly diagnosed head
and neck squamous cell carcinoma (HNSCC). These can be
divided into patient-related, tumour-related and/or treatment-
related parameters. Traditional tumour-related factors
currently used in the therapeutic decision are primary
tumour location and extension, nodal involvement and
distant metastatic spread. Patient-related factors such as
age, co-morbidity (cirrhosis, emphysema etc.) or patients'
performance status are also important for the decision
regarding the specific choice of the therapeutic modalities to
be recommended.
Histological grading based on Broders' initial classification
(Broders, 1920) is a standard pathological diagnostic
parameter, with recognised value in different oncological
entities. This, however, has not been consistently substan-
tiated in HNSCC owing to the inherent subjectivity in the
grading systems (Ensley et al., 1986; Roland et al., 1992).
Extensive scoring methods have been introduced to
histological grading to minimise subjectivity and to improve
the prognostic accuracy (Jacobsson et al., 1973; Crissman et
al., 1984; Anneroth et al., 1986; Zatterstrom et al., 1991;
Barona de Guzman et al., 1993).
Recently, specific factors such as qualitative and
quantitative cytokeratin expression (Van der Velden et al.,
1993, Klijanienko et al., 1993) tumour vascularisation
(tumour invasion of vessels and angiogenesis) (Weidner et
al., 1991) and tumour DNA content have been evaluated.
The value of ploidy as an independent prognostic parameter
in heterogeneous solid tumours remains moot and contro-
versial (Merkel and McGuire, 1990) and seems to be linked
to treatment modalities (Ensley and Maciorowski, 1994). It
has been reported that aneuploid tumours are more
chemosensitive (Gregg, 1993) but the correlation with
response to radiotherapy is not clear (Walter et al., 1991;
Ensley and Maciorowski, 1994).
Determining tumoral proliferative activity has been a
subject of interest for many decades (Tubiana, 1993) and a
number of semiroutine immunohistochemical techniques has
recently become available for its determination [Ki-67,
proliferating cell nuclear antigen (PCNA), bromodeoxyur-
idine (BUDR)]. Highly proliferative tumours can benefit from
particular radiotherapeutic modalities (Begg et al., 1990).
However, none of these histobiological factors has been
confirmed to have a better prognostic value than clinical
staging by the TNM classification.
The present prospective study was designed (1) to address
the relationship between clinical, histological and/or biologi-
cal factors in HNSCC, (2) to compare the prognostic weight
ofhistological and biological factors to that of known clinical
prognostic factors.
To this effect, all previously untreated and newly
diagnosed patients with a single primary HNSCC tumour,
treated over 1 year in our institution, were prospectively
biopsied for diagnosis. A simplified version of Crissman and
Jacobsson criteria of histological grading and differentiation
as complemented with histological and immunohistochemical
determination of keratins, mitotic index and vascular count.
Their quantification was subjected to inter- and intraobserver
validation assessment.
Tumoral ploidy (DNA index and S-phase percentage) was
also determined on fresh tissue samples. All these parameters
were validated for feasibility and variance through semi-
quantitative and qualitative scales. The interrelationship of
these factors has been reported elsewhere (De Braud et al.,
1991) and will not be detailed here. Their eventual prognostic
weight was statistically analysed and correlated with clinically
relevant end points of treatment outcome, clinical progression
pattern and overall survival.
In the present paper we report the prognostic impact of
parameters studied on the overall survival and cumulative
incidence of locoregional failures and metastases with a
minimum follow-up of 2 years.
Materials and methods
Patients
The initial materials for this study consisted of 148
consecutive specimens from newly diagnosed and untreated
patients with HNSCC biopsied for diagnosis and the present
study in our institution between August 1989 and September
1990. Of these, 11 biopsies were not suitable for analysis
(small samples, technical problems, negative biopsies) and 15
patients had multiple primary tumours diagnosed simulta-
neously in head and neck sites.
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The biopsy site and tumoral tissue sampling methodology
was limited by the tumoral site and volume, i.e. in T3-T4
tumours evaluated under general anaesthesia multiple
biopsies were taken, and only the tumoral periphery non
necrotic samples were subjected to the prospective methodol-
ogy; in small (TI -T2) tumours biopsied under local
anaesthesia a single specimen was available for processing.
Among the remaining 122 patients, three had distant
metastases at initial presentation, four had another simulta-
neous malignancy (breast, oesophagus, liver) and seven
patients could not be treated with curative intention
(incomplete treatment). The remaining 108 patients who
received a complete treatment, formed the population in the
present study (Table I).
There were 94 (87%) men and 14 (13%) women
representing five different primary tumour sites: oral cavity
(24 patients, 22%), oropharynx (40 patients, 37%),
hypopharynx (20 patients, 19%), epilarynx (13 patients,
12%), larynx (11 patients, 10%). The median age at
diagnosis was 58 (mean 57, range 32-78). Based on clinical
grounds and similarities in natural history, we combined oral
cavity and oropharynx for statistical analysis (group I: 64
patients), as well as hypopharynx and epilarynx (group II: 33
patients); patients with laryngeal tumours formed the third
group (group III: 11 patients). Epilaryngeal tumours (that is
the suprahyoid part of the epiglottis, the aryepiglottic fold
and the arytenoid) have been grouped with hypopharynx
given its clinical behaviour (lymph node involvement,
lymphatic and metastatic spread) closer to hypopharyngeal
tumours than laryngeal ones.
All tumours were classified according to the TNM of the
International Union Against Cancer (UICC-AJCC 1987)
which is shown in Table I: 36 (33%) patients had TI or T2
tumours, 72 (67%) had T3 or T4 tumours; 47 (44%) patients
were classified as NO, 40 (37%) as NI, N2a or N2b and 21
(19%) as N2c or N3.
Treatments
At the Institut Gustave Roussy treatment planning and
protocol assignment are determined prospectively for all new
HNSCC patients by a multidisciplinary committee. Prether-
apeutic work-up consists of a triple endoscopy, chest
radiograph and a locoregional computerised tomography
(CT) scan, except for patients with small tumours and NO
status. A liver ultrasound and a bone scan are included if
there is clinical or biological suspicion of metastasis.
The first treatment modality used was surgery in 48 cases
(first group: 44%), neoadjuvant chemotherapy in 29 cases
(second group: 27%), whereas radiotherapy was the initial
therapeutic modality in 31 cases (third group: 29%). In the
first group, 44/48 (92%) patients were treated with surgery
followed by post-operative radiotherapy, and four (8%) with
surgery alone. When surgery was a therapeutic step, it
involved intraoperative frozen section evaluation of surgical
resection margins. In surgical procedures following neoadju-
vant chemotherapy the extent of appropriate surgical
resection of the tumour was decided before chemotherapy.
In the second group 12/29 patients (41%) were subsequently
treated with surgery and radiotherapy, 15 (52%) with
conventional radiotherapy, one with surgery alone and one
with simultaneous chemoradiotherapy. The third treatment
Table I Numbers of patients in each T and N subgroup
Ti T2 T3 T4 Total
NO 6 15 13 13 47
NI 1 3 7 7 18
N2a 0 4 2 3 9
N2b 0 4 5 4 13
N2c 0 2 6 5 13
N3 0 1 3 4 8
7 29 36 36 108
Table II First treatment and clinical parameters
Surgery Chemotherapy Radiotherapy Total
<60 years 25 15 13 53
60 years 23 14 18 55
TI 3 0 4 7
T2 16 5 8 29
T3 16 13 7 36
T4 13 11 12 36
NO 20 11 16 47
NI 8 4 6 18
N2a 3 2 4 9
N2b 9 3 1 13
N2c 7 4 2 13
N3 1 5 2 8
Oral cavity 6 8 10 24
Oropharynx 14 10 16 40
Hypopharynx 13 5 2 20
Epilarynx 7 4 2 13
Larynx 8 2 1 11
group was more heterogeneous: 17/31 patients (55%) received
conventional radiotherapy, 11 (35%) patients had very large
tumours treated either with hyperfractionation radiotherapy
(seven patients) or with simultaneous chemoradiotherapy
(four patients) and finally, four had small Ti tumours treated
with brachytherapy.
The distribution of patients according to first treatment
and clinical factors is given in Table II.
Histological examination
Fresh biopsies were fixed in formalin and embedded in
paraffin. The quality of material was checked by frozen
sections. Sections (4 yim) were stained with haematoxylin and
eosin for histological evaluation, vascular count (TV) and
mitotic index (MI).
Different histological parameters were evaluated and
tumours were graded as follows: well- (WD), moderately
(MD) and poorly differentiated (PD) depending on the degree
of keratin pearl formation, keratinisation and overall
resemblance of carcinoma to normal squamous epithelium
according to World Health Organization criteria (World
Health Organization, 1978). Other parameters were assessed
according to a modification of grading system (Crissman et
al., 1984): degree of keratinisation (1, strongly keratinised; 2,
keratinised; 3, slightly keratinised; 4, unkeratinised); nuclear
grade (1, regular nuclei; 2, slight atypia; 3, strong; 4, severe);
growth pattern (1, pushing borders; 2, large sheets; 3, fine
sheets; 4, isolated cells); desmoplasia (1, hyalinised; 2, fibrous;
3, partially fibrous; 4, oedema); inflammatory infiltrates (1,
acute; 2, subacute; 3, chronic or small infiltrates; 4, not
inflammatory).
TV and MI were counted at x 400 (31 x 31 Mm) in ten
consecutive randomly chosen fields in the area of high
capillary density (angiogenesis). Fields presenting less than
50% of tumour tissue were eliminated. Vascular dilated
areas, haemorrhagic and necrotic or fibrotic areas were
omitted. TV was evaluated as a numeric score of all sections
of all anatomical types of vessels (with or without
erythrocytes). MI was counted in the same fields analysed
for vascularisation. For MI the cut-off point was 25 mitosis
per ten high-power fields (HPFs). For TV, we tested three
different cut-off points: 20, 30, 40 vessels x ten HPFs.
Vascular invasion by tumour cells were also determined for
each biopsy in the peripheral microvessels. Tumour emboli in
the vascular micronetwork was defined as absent or present.
The quantitative score regarding tumour vascularisation
and mitotic index was established through two separate
evaluations by the same pathologist (JK, intraobserver
variance) as well as readings by three other pathologists
(intraobserver variance). The second reading by the original
pathologist (JK) was chosen as the set of data to be analysed,
having the smallest variance. Results with variance analysis
of intra- and inter-observer variations has already beenreported (Klijanienko et al., 1995). The distribution of
patients according to first treatment and histological
parameters is presented in Table III).
Immunohistochemical keratin staining was carried out on
unstained paraffin-embedded sections, with the use of the
peroxidase -antiperoxidase method as described previously
(Klijanienko et al., 1989). All slides were reviewed by light
microscopy and processed for automated image analysis
(SAMBA 2005). The antibodies used and their specification
were:
* KLI (Immunotech, ref. 0128, Luminy, France) identifies
cytokeratin protein between 55 and 57 kDa, corresponding
to keratin 6.
* K19 (Progen, ref. 19.1, Heidelberg, Germany) identifies
the cytokeratin of 40 kDa, which is expressed preferen-
tially in basal layer of mucosal epithelia.
* K13 (Progen, ref. 13.1, Heidelberg, Germany) recognises
the cytokeratin of 54 kDa, present in the suprabasal cell
layers of all normal stratified mucosal epithelia.
Immunohistochemical staining was evaluated in corn
pearls (P) and in tumour cells (T). K13 and K19 were
considered positive if more than 25% of surface area of P or
T were stained. KLI was considered positive if more than
50% of surface area of P or T were stained.
Cytofluorometric analysis ofploidy and S-phase fraction
Fresh specimens obtained directly from biopsies of the
primary tumour were transported on ice in a sterile saline
or in Hanks' balanced salt solution (HBSS) and were stored
at 4°C in the same medium for a maximum of48 h before the
analysis. A cell suspension was obtained according to the
technique reported by Ensley et al. (1987). Briefly, small
tumour samples (average weight 130 mg) were dissociated
enzymatically in a cocktail of collagenase II (0.5 mg ml-'),
DNAase I (0.002%) and trypsin (0.25%) agitated for 1 h at
37°C. If dissociation was not complete, the procedure was
repeated with a freshly prepared enzyme solution. Cells were
then washed and resuspended in HBSS -50% fetal calf
serum; viability was established by trypan-blue staining and
the cells were fixed on ice by adding 70% ethanol and stored
at 4°C for at least 30 min. Finally 2 x 10 ml were stained with
propidium iodide (0.05 mg ml-') and analysed in an Epics
750 (Coulter SPA) flow cytometer, 488 nm at 300 mW,
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LP 550 blocking filter, SP 600 as splitting filter, LP 630+
BP 635 on red photomultiplier (RPMT). Cells were gated on
forward angle light scatter (FALS) and 900 scatter to elimi-
nate doublets, 10 000 events were analysed. The histograms
were compared with a known diploid control from normal
lymphocytes, defined as having DNA index= 1.0 (DI). Any
cell population with DI> 1.1 was considered as aneuploid.
S-phase fraction was calculated on histograms according
to the method described by Baisch et al. (1975). The average
cellular field, based on weight of the tumour specimen, was
18 x 106 cells g-I in the aneuploid samples and 38 x
106 cells g-' in the diploid ones. The S-phase was deter-
mined on an average 2.4 x 106 cells in the aneuploid cases and
5.48 x 106 cells in the diploid ones. Only 80 samples in our
cohort were technically adequate to establish ploidy, whereas
50 of them had an adequate number of cells to determine the
S-phase fraction. This is in agreement with other published
experiences based on small HNSCC biopsies. Patient
distribution according to first treatment and immunohisto-
chemical and ploidy analysis results is shown in Table IV.
All histopathological assessments, ploidy and S-phase
determinations were performed blind to the patients
characteristics, treatment and outcome.
Follow-up
Patients were followed up quarterly with clinical examination
of the head and neck and routine chest radiograph. A liver
ultrasound and a bone scan were included if there was
clinical or biological suspicion of metastasis. Patients' clinical
status was reviewed in January 1993, that is 26 months after
the last patient was included in the study. There were no
follow-up losses. The median follow-up is 32 months (range
26-38). The cut-off date for analysis was 1 January 1993.
Statistical analysis
The semiquantitative variables were analysed in two groups
(I+II vs III+IV) and qualitative and semiquantitative
variables were displayed in contingency tables and analysed
by the chi-square test (with Yates' correction when
appropriate).
The prognostic value of all mentioned parameters was
studied in univariate analysis for three end-points: overall
Table m Histological parameters and first treatment given
Surgery Chemotherapy Radiotherapy Total
Differentiation
PD 16 6 7 29
MD+WD 32 23 24 79
Nuclear grade
I+II 21 13 15 49
III+IV 27 16 16 59
Keratinisation
I+11 24 19 24 67
III+IV 24 10 7 41
Desmoplasia
I+II 20 5 9 34
III +IV 28 24 22 74
Growth pattern
I+II 20 13 14 47
III+IV 28 16 17 61
Inflammation
I+II 25 18 22 65
III +IV 23 11 9 43
Vascular invasion
No 28 20 26 74
Yes 20 9 5 34
Vascular count (105 patients)
TV <29 27 11 13 51
TV >29 20 18 16 54
Mitotic index (105 patients)
MI <25 25 13 15 53
MI >25 22 16 14 52Clinicopathological parameters in HNSCC
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Table IV Number of patients receiving first treatment and tumour DNA ploidy,
keratin immunohistochemistry
Surgery Chemotherapy Radiotherapy Total
S-Phase (50 patients)
< 10% 10 4 3 17
> 10% 17 6 10 33
Ploidy (80 patients)
D 17 6 11 34
A 22 13 11 46
Keratin 13 (106 patients)
Negative 33 14 15 62
Positive 15 14 15 44
Keratin 19 (107 patients)
Negative 31 18 21 70
Positive 17 10 10 37
Kerative (102 patients)
Negative 29 11 11 51
Positive 18 16 17 51
Table V Clinical and tumour progression
No evidence of disease 53 Nodal failure only 3
Local failure only 15 Nodal + metastases 4
Local +nodal failure 4 Metastases only 14
Local +metastases 4 Second cancer 6
Local +nodal+metastases 3 Dead, other causes 2
survival, cumulative incidence of locoregional failures,
cumulative incidence of metastases. The Kaplan-Meier
method was used for estimation of survival curves. The
event-specific incidences were obtained by subtracting the
Kaplan-Meier estimate of event-specific free survival from 1
(Kaplan and Meier, 1958). The overall survival was
calculated as the time from first treatment to either the date
of death (whatever the cause) or to the date of last follow-up.
The locoregional failure free-survival was calculated from the
date of first treatment to the date of first locoregional relapse
with or without metastases. All other events (second cancers,
isolated metastases) were censored. For the metastasis-free
survival, the date of the first metastasis (with or without
locoregional relapse) was used, all other events were
censored. The log-rank test was used to compare survival
curves (Mantel, 1966). All reported P-values are two-sided.
The event rates are given with their standard deviation (s.d.).
Multivariate analysis was used to determine the indepen-
dent prognostic value of the selected variables, using Cox's
proportional hazards regression model with a forward
stepwise regression (Cox, 1972). It was performed for each
end point, taking into the model all the variables with a P-
value <0.02 in the univariate analysis. These analyses were
stratified on tumour site because the evaluation of the
prognostic value of tumour site was not the main aim of
this study.
Results
Histobiological studies
Tables III and IV present the distribution of patients
according to primary treatment and histobiological para-
meters.
The correlation between histopathological and biological
parameters is being reported in detail elsewhere (Klijanienko
et al., 1995). In summary, our results show:
* K13 and 19 are co-expressed in 57% of tumours, K19
expression was more prevalent in MD and PD subtypes,
while K13 was more evident in WD carcinomas. No
correlation of K13 and K19 expression with TNM stages
or primary tumour site was observed.
* There was a strong relationship between poor differentia-
tion and high N stage: 4/29 (14%) of patients with poorly
differentiated and 43/79 (54%) with well- or moderately
differentiated tumours were classified NO (P<0.001).
* Keratinisation (P<0.001), as well as KLI immunostaining
(P=0.02) were positively correlated with differentiation.
* Vascular invasion by tumour cells was statistically more
frequent in tumours with clinically involved nodes (25/61,
41%) than in tumours without nodal disease (9/47, 19%),
P=0.015.
* Vascular invasion was found in 1 of 11 laryngeal tumours
(9%), 18/64 (35%) of oropharynx/oral cavity tumours,
and in 15 of 33 (45%) hypopharynx/epilarynx tumours.
* Forty-six (57%) tumours were found to be aneuploid and
34 (43%) diploid. Though aneuploidy was more frequent
in hypopharyngeal primary tumours (63% vs 55%) and in
tumours with nodal involvement (63% vs 50%), these
associations were not statistically significant.
Patient status
Clinical and tumour events (Table V) By January 1993, 39
patients (36%) had died from their HNSCC: seven (6%)
from intercurrent disease (two patients) or second primaries
(five patients); six (6%) patients are alive with disease and 56
(52%) patients are alive with no evidence of disease (3 of
these 56 patients had a local recurrence that could be
retreated curatively by salvage treatment).
The clinical progression of the 53 (49%) patients is
presented in Table V. There were 33 (31%) locoregional
failures (with or without metastases) and 25 (23%) metastases
(with or without locoregional failure). Six patients presented
with a second cancer.
The histopathological assessment of surgical specimens in
our study revealed 12 cases in which margins were positive
for tumour or too close for comfort (doubtful) among 61
cases submitted to surgery. Eleven of those cases were among
the 48 patients having surgery as the initial therapeutic
procedure, whereas one case was among the 29 patients
having neoadjuvant chemotherapy.
Two patients of the 11 with positive margins in the initial
surgery group had local recurrence (on primary tumour site),
whereas three had a neck recurrence. In the 37 patients of the
surgery first group in which margins were considered
adequate, there were eight local recurrences and three nek
recurrences (two of them both neck and primary). In the 11
patients with neoadjuvant chemotherapy in which surgical
margins were negative and adequate, there was a single local
recurrence. The differences are not statistically significant.
Univariate analysis (Table VI)
Overall survival The overall 2 year survival was 65.5%
(+0.05), whereas the disease-free survival at 2 years was
50%. The possible impact ofclinical (age, sex, primary site, T
and N stage) and biological factors was investigated by
univariate analysis: age (<60 vs >60, P=0.02), siteClinicopathological parameters in HNSCC
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Patients (n=108)
Age
<60 53
>60 55
Sex
M 94
F 14
Site
OC+OP 64
HP+EL 33
L 11
T
T1+T2 36
T3 +T4 72
N
NO 47
N 1 61
Differentiation
PD 29
MD+WD 79
Nuclear grade
I+II 49
III + IV 59
Keratinisation
I+II 67
III +IV 41
Desmoplasia
I+II 34
III +IV 74
Growth pattern
I+II 47
III +IV 61
Inflammation
I+II 65
III +IV 43
Vascular invasion
No 74
Yes 34
S-phase
<10% 17
> 10% 33
Ploidy
D 34
A 46
TV
<29 51
>29 54
MI
<25 53
>25 52
K 13
- 62
+ 44
K 19
- 70
+ 37
K 6
- 51
+ 51
Table VI Prognostic factors analysed by univariate analysis
Overall survival (s.e. %) Locoregionalfailures (s.e. Metastases (s.e. %)
2 year rate %) 2 year rate
2 year rate
P-value P-value P-value
75 (6)
56 (7)
66 (5)
64 (13)
67 (6)
55 (9)
90 (9)
75 (7)
61 (6)
76 (6)
57 (6)
66 (9)
65 (5)
59 (7)
71 (6)
64 (6)
68 (7)
68 (8)
65 (6)
70 (7)
62 (6)
67 (6)
63 (7)
66 (6)
65 (8)
65 (12)
64 (8)
65 (8)
62 (7)
59 (7)
76 (6)
64 (7)
71 (6)
66 (6)
65 (7)
64 (6)
68 (8)
66 (7)
67 (7)
0.02 326 (76)
0.32 30 (5) 14 (9)
30 (6)
0.04 29 (8)
20 (13)
0.21 21 (7) 36 (6)
0.01 323 (6)
0.15 28 (59)
0.18 32 (7) 25 (6)
0.75 31 (6) 0.5 23 (7)
35 (8) 0.76 30 (6)
0.54 27 (7) 29 (6)
0.77 29 (6) 0.7 28 (7)
0.75 27 (5) 0.5 31(8)
0.56 30 (11) 36 (9)
0.74 34 (8) 27 (7)
0.38 30 (7) 23 (6)
0.71 239 (6)
0.85 29 (6) 26 (7)
0.72 32 (6) 23 (7)
0.98 27 (6) 27 (7)
0.33
0.19
0.65
0.06
0.13
0.82
0.24
0.69
0.86
0.71
0.98
0.34
0.61
0.68
0.21
0.25
0.85
0.80
0.95
14 (5)
32 (7)
22 (4)
30 (13)
20 (5)
32 (9)
18 (12)
9 (5)
30 (6)
6 (4)
36 (6)
42 (9)
15 (4)
20 (6)
25 (6)
14 (4)
35 (7)
22 (8)
23 (5)
15 (5)
29 (6)
18 (5)
30 (7)
17 (4)
36 (9)
24 (10)
26 (8)
25 (8)
25 (7)
30 (7)
15 (5)
22 (6)
23 (6)
25 (6)
19 (6)
20 (5)
29 (8)
28 (7)
15 (5)
0.02
0.60
0.22
0.01
0.0004
0.001
0.99
0.007
0.98
0.17
0.16
0.02
0.71
0.83
0.11
0.89
0.69
0.22
0.09
.0
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(hypopharynx +epilarynx vs oral cavity +oropharynx vs
larynx; P=0.04) and N stage (NO vs NI-2-3, P=0.Ol)
(Figure 1), were the only significant factors for overall
survival. Histological parameters, as well as ploidy or 5-
phase, did not reveal any statistically significant effect on
survival.
Cumulative incidence oflocoregionalfailures The cumulative
incidence of locoregional failures with or without metastases
at 2 years is 31% (±0.04). The only factor with borderline
significance in univariate analysis was T stage (Ti +T2 vs
T3+T4, P=0.06).
Cumulative incidence ofmetastases The cumulative incidence
of metastases with or without locoregional failures at 2 years
is 24% (±0.04). Significant clinical factors were nodal status
(NO vs NI- 2 -3) (Figure 2) (P=0.0004), age (P=0.02) and T
stage (P=0.01). Three histological factors were also
significant: histological grading (PD vs WD+MD) (Figure
3), keratinisation and vascular invasion. Patients with poorly
differentiated tumours (P<0.001), with a low degree of
keratinisation (P<0.07), with vascular invasion (P<0.02)
had a higher incidence of metastases. The most discriminative
prediction of metastatic likelihood was obtained when the
NI-2-3 and PD parameters were associated with 50%
incidence of distant metastases after a 2 year follow-up.
Thirty-five per cent of patients in this group developed
metastasis within 1 year of diagnosis (Figure 4).
Multivariate analysis (Tabke VII)
Overall survival Only age and nodal status were significantly
correlated with survival. T stage, differentiation and nuclear
grade did not contribute further prognostic information.
Locoregionalfailures T stage was the only significant factor
associated with locoregional failures.
Cumulative incidence of metastases Age, T stage, N status
and histological differentiation were significantly correlated
with incidence of metastases, whereas keratinisation and the
presence of vascular invasion did not contribute further
information.
Discussion
The increasing complexity of management strategies for
patients with head and neck squamous carcinoma requires
new objective prognostic parameters to subdivide patients. In
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Table VII Prognostic factors analysed by multivariate analysis
Significant prognostic Relative 95% confidence
Endpoints factora P-value risk interval
Overall survival Age (<60; >60) 0.02 2.1 1.1-3.8
N (N+/N0) 0.04 1.9 1.1-3.7
Cumulative incidence
of locoregional
failure T (T3+T4/Tl +T2) 0.06 2.2 0.97-5.2
Cumulative incidence
of metastases Age (<60; >60) 0.008 3.4 1.4-8.3
T (T3+T4/T1+T2) 0.01 4.8 1.3-16.9
N (N+/NO) 0.04 4.3 1.2-15.5
Differentiation
(PD/WD+MD) 0.04 2.6 1.1-6.2
aNon-significant prognostic factors: for overall survival, differentiation and nuclear grade;
for cumulative incidence oflocoregional failure, N; for cumulative incidence of metastases,
keratinisation and vascular invasion.
most prognostic studies several clinical entities are grouped
under the single heading of head and neck squamous cancer.
The co-morbidity associated with this patient population and
the primary therapeutic pattern (surgery vs radiother-
apy±chemotherapy) in the different medical environments
(country, institution, treatment philosophy) add to the
heterogeneity within published series dealing with prognostic
issues. This makes the interpretation ofmany published series
difficult.
Our prospective consecutive non-selected patient series is a
clear illustration of the heterogeneous nature of this patients'
population and reflects the everyday problem of treatment
choice. Despite some problems, the management ofhead and
neck cancer patients has improved. Current therapeutic
management is effective and provides better local control,
fewer locoregional recurrences and less frequent, less
mutilating surgery. These changes are reflected in the
increase of reported mortality due to metastatic disease.
Unfortunately there has been little improvement in overall
survival.
Our study had two aims within its prospective methodol-
ogy: the first was the assessment of the reliability and
feasibility of different techniques in a routine clinical setting.
The second was the determination of their prognostic weight
against three different clinically relevant end points (overall
survival, cumulative incidence oflocoregional recurrences and
cumulative incidence of metastases). The prognostic weight
was ascertained with standard univariate and multivariate
statistical methods. A systematic clinical work-up and follow-
up routine with a minimum follow-up of 2 years and no
follow-up losses in this patient population accrued in 1 year
strengthens the clinical relevance of our findings.
The prognostic value of the TNM system is once again
confirmed. Our study also confirms that poorly differentiated
tumours generate more and larger nodal metastases, as
previously described (Roland et al., 1992). The multivariate
analysis shows that, within the same T and N stage, these
poorly differentiated tumours metastasise earlier and more
frequently than well- or moderately differentiated ones. In
this respect, the cumulative incidence of metastasis is shown
to be particularly steep in its rate and as high as 50% in
certain subpopulations (Figures 2-4). Patients with poorly
differentiated tumours and clinical nodal involvement are at
high risk. Any therapeutic intervention aiming to eradicate or
postpone the metastatic process should focus on this patient
population. Our study also shows that an experienced
histopathologist is still the most powerful and discriminating
prognostic factor after a clinical examination and careful
staging with currently available technology has been
obtained. Of note is the fact that our attempt to improve
the discriminative power of currently available grading
systems did not succeed. The reliability of histological
grading was proven by close inter- and intraobserver
correlation.
Given these results, the relationship between histological
differentiation and response to systemic treatment in HNSCC
is of particular interest. For example, Nakashima et al. (1990)
using an in vitro test of chemosensitivity have suggested that
intrinsic cell chemosensitivity correlated with poor differ-
entiation. In advanced tumours treated with combined
cisplatin and radiation therapy complete response has been
shown to be more frequent in the subgroup of poorly
differentiated tumors (Crissman et al., 1987). Complete
response with induction chemotherapy alone correlated
poorly with conventional differentiation (Ensley et al., 1987)
or with other histological parameters (Ensley et al., 1988).
However, in advanced laryngeal tumours, the histological
parameter 'pattern of invasion' correlated strongly with
response to primary chemotherapy (Bradford et al., 1994).
The recent association between vascular density and
tumour aggressivity described initially in breast cancer has
also been reported in HNSCC (Gasparini et al., 1993). Both
the present paper and Van Hoefet al. (1993) regarding breast
cancer patients have failed to confirm the clinical prognostic
relevance of this new parameter. In this study, cytofluoro-
metric analysis was performed on fresh samples, as
recommended by Ensley and Maciorowski (1994). Unlike
these authors, but similar to Coolse et al. (1994), we did not
find any correlation between clinical outcome and cyto-
fluorometric parameters.
We contend that the likelihood of identifying clinically
valid new prognostic factors in a non-selected population of
HNSCC patients is very low. The search for new tools to aid
in the therapeutic decision process is likely to be more
successful in specific clinical subpopulations, i.e. site-specific
(larynx, nasopharynx), low nodal stage and in poorly
differentiated tumours. Similarly, prospective therapeutic
trials, with clinically relevant end points should be
performed in specific patient populations to maximise
discriminating power.
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